Targeting Online Sales of Fentanyl Act
The source supplies the latest action, but no lifecycle stage.
Latest action (22 Mar 2024): Referred to the Subcommittee on Innovation, Data, and Commerce.
What this bill does
The Targeting Online Sales of Fentanyl Act would require the U.S. Government Accountability Office (GAO) to conduct a comprehensive study on the online sale of fentanyl and methamphetamine. This study would examine how these drugs are sold online, including business models, supply chains, and customer acquisition strategies. It would also look into how financial transactions occur, with a specific focus on impacts on individuals aged 18 and younger, and assess current federal efforts to combat these online sales.
The bill also mandates the GAO to review collaboration among federal agencies, and with state, tribal, local, and foreign governments, as well as the private sector. The study will analyze federal law enforcement procedures for investigating and prosecuting online drug sales, identify gaps in coordination and resources, and examine the technologies and enforcement mechanisms used by online platforms to detect and prevent sales. Finally, it will analyze the number and outcomes of referrals from online providers to the federal government.
This bill was introduced in the House of Representatives on March 19, 2024, and referred to the Committees on Energy and Commerce and the Judiciary. It has not yet been voted on by either chamber of Congress. If enacted, the GAO would have one year from the date of enactment to submit its report to Congress.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
22 Mar 2024
Referred to the Subcommittee on Innovation, Data, and Commerce.
Common questions
- What does H.R. 7730 do?
- The Targeting Online Sales of Fentanyl Act would require the U.S. Government Accountability Office (GAO) to conduct a comprehensive study on the online sale of fentanyl and methamphetamine. This study would examine how these drugs are sold online, including business models, supply chains, and customer acquisition strategies. It would also look into how financial transactions occur, with a specific focus on impacts on individuals aged 18 and younger, and assess current federal efforts to combat these online sales. The bill also mandates the GAO to review collaboration among federal agencies, and with state, tribal, local, and foreign governments, as well as the private sector. The study will analyze federal law enforcement procedures for investigating and prosecuting online drug sales, identify gaps in coordination and resources, and examine the technologies and enforcement mechanisms used by online platforms to detect and prevent sales. Finally, it will analyze the number and outcomes of referrals from online providers to the federal government. This bill was introduced in the House of Representatives on March 19, 2024, and referred to the Committees on Energy and Commerce and the Judiciary. It has not yet been voted on by either chamber of Congress. If enacted, the GAO would have one year from the date of enactment to submit its report to Congress.
- Has H.R. 7730 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 7730. Check the latest action and official source below.
- Who sponsored H.R. 7730?
- H.R. 7730 was sponsored by Rep. Spanberger, Abigail Davis [D-VA-7] (D-VA), with 4 cosponsors.
- What's the latest action on H.R. 7730?
- Referred to the Subcommittee on Innovation, Data, and Commerce. (22 Mar 2024).
Related bills in Crime and Law Enforcement
Enhancing Detection of Human Trafficking Act
National Coordination Center and Commercial Cyber Capabilities Codification Act
Supporting the goals and ideals of "National Nonviolence Week" to raise awareness of youth violence in the United States.
Anthony Amoros Law Right to Know Act
More bills from Rep. Spanberger, Abigail Davis [D-VA-7]
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.